The Health Sciences Authority has convened an expert advisory committee to review the risk-benefit balance of COX-2 selective and non-selective NSAIDs. The Committee comprised 11 experts representing relevant specialties and expertise, viz rheumatology, cardiology, gastroenterology, colorectal surgery, pharmacology, orthopaedic surgery, family medicine, dermatology, pharmacy and pharmacovigilance. More details.
 |
The Health Sciences Authority has convened an expert advisory committee meeting to review the risk-benefit balance of COX-2 selective and non-selective NSAIDs following the recent emerging concerns on the safety of this class of drugs. The committee comprised experts from relevant specialties and expertise. More details.
|
